STOCK TITAN

Sanofi files 6-K on USD 3 billion bond pricing announcement

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Sanofi furnished a Form 6-K noting a press release titled “Sanofi successfully prices USD 3 billion of bond issue.” The filing indicates the company priced a USD 3 billion bond and includes the press release as Exhibit 99.1.

The press release is dated October 28, 2025, and is incorporated by reference in the submission.

Positive

  • None.

Negative

  • None.

Insights

Neutral financing disclosure of a USD 3 billion bond.

Sanofi reported that it priced a USD 3 billion bond, with the associated details contained in a press release incorporated as Exhibit 99.1. The 6-K serves as a formal notice of this financing activity.

As presented, this is an administrative update confirming the transaction amount and the availability of the press release for specifics. Any evaluation of cost of capital, maturity profile, or structure would be based on the referenced exhibit.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the month of October 2025

Commission File Number: 001-31368

SANOFI

(Translation of registrant’s name into English)

46, avenue de la Grande Armée, 75017 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒  Form 40-F

 

1


In October 2025, Sanofi published the press release attached hereto as Exhibit 99.1 which is incorporated herein by reference.

Exhibit Index

 

Exhibit No.

  

Description

Exhibit 99.1    Press Release dated October 28, 2025: Sanofi successfully prices USD 3 billion of bond issue

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: October 28, 2025       SANOFI
    By  

/s/ Alexandra Roger

      Name: Alexandra Roger
      Title: Head of Legal Corporate & Finance

 

3

FAQ

What did Sanofi (SNY) report in this 6-K?

Sanofi noted a press release titled “Sanofi successfully prices USD 3 billion of bond issue,” incorporated as Exhibit 99.1.

How large is Sanofi’s bond issue mentioned in the filing?

The filing references a bond issue of USD 3 billion.

When is the referenced Sanofi press release dated?

The press release is dated October 28, 2025.

Where can investors find more details on the bond pricing?

Details are contained in Exhibit 99.1, the incorporated press release.

What is the purpose of this Sanofi Form 6-K?

It furnishes notice of the press release and incorporates it by reference into the submission.
Sanofi FR

NASDAQ:SNY

View SNY Stock Overview

SNY Rankings

SNY Latest News

SNY Latest SEC Filings

SNY Stock Data

106.22B
2.41B
Drug Manufacturers - General
Healthcare
Link
France
Paris